National Bank of Canada’s Elevation Oncology ELEV Stock Holding History

National Bank of Canada’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-40,000	Closed	-$14.7K	–	2949
2025 Q2	$14.7K	Buy	40,000 +10,000	+33%	+$3.34K	﹤0.01%	2253
2025 Q1	$7.71K	Buy	+30,000	New	+$17.1K	﹤0.01%	2298

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

National Bank of Canada's ELEV Position: Q3 2025 in Review

National Bank of Canada sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 40,000 shares — an estimated $14.7K sold.

National Bank of Canada first reported a position in ELEV in Q1 2025 and held it in 2 quarters. The position peaked at $14.7K in Q2 2025. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

National Bank of Canada reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
National Bank of Canada sold 40,000 Elevation Oncology shares in Q3 2025, an estimated $14.7K.
National Bank of Canada first reported a position in Elevation Oncology in Q1 2025 and held it in 2 quarters.
National Bank of Canada's Elevation Oncology position peaked at $14.7K in Q2 2025.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on National Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.